Small Molecules Targeting the Disordered Transactivation Domain of the Androgen Receptor Induce the Formation of Collapsed Helical States

Abstract

AbstractCastration-resistant prostate cancer (CRPC) is a lethal condition suffered by ∼35% of prostate cancer patients who become resistant to existing FDA-approved drugs. Small molecules that target the intrinsically disordered N-terminal domain of the androgen receptor (AR-NTD) have shown promise in circumventing CPRC drug-resistance. A prodrug of one such compound, EPI-002, entered human trials in 2015 but was discontinued after phase I due to poor potency. The compound EPI-7170 was subsequently found to have improved potency, and a related compound entered human trials in 2020. NMR measurements have localized the strongest effects of these compounds to a transiently helical region of the disordered AR-NTD but no detailed structural or mechanistic rationale exists to explain their affinity to this region or the comparative potency of EPI-7170. Here, we utilize all-atom molecular dynamics simulations to elucidate the binding mechanisms of the small molecules EPI-002 and EPI-7170 to the disordered AR-NTD. We observe that both compounds induce the formation of collapsed helical states in the Tau-5 transactivation domain and that these bound states consist of heterogenous ensembles of interconverting binding modes. We find that EPI-7170 has a higher affinity to Tau-5 than EPI-002 and that the EPI-7170 bound ensemble contains a substantially higher population of collapsed helical states than the bound ensemble of EPI-002. We identify a network of interactions in the EPI-7170 bound ensemble that stabilize collapsed helical conformations. Our results provide atomically detailed binding mechanisms for EPI compounds consistent with NMR experiments that will prove useful for drug discovery for CRPC.SummaryIntrinsically disordered proteins (IDPs), which do not fold into a well-defined three-dimensional structure under physiological conditions, are implicated in many human diseases. Such proteins are difficult to characterize at an atomic level and are extremely challenging drug targets. Small molecules that target a disordered domain of the androgen receptor have entered human trials for the treatment of castration-resistant prostate cancer, but no structural or mechanistic rationale exists to explain their inhibition mechanisms or relative potencies. Here, we utilize molecular dynamics computer simulations to elucidate atomically detailed binding mechanisms of these compounds and understand their inhibition mechanisms. Our results suggest strategies for developing more potent androgen receptor inhibitors and general strategies for IDP drug design.